.
MergerLinks Header Logo

Announced

Completed

Novo completed the acquisition of KabaFusion from Pritzker Private Capital.

Financials

Edit Data
Transaction Value-
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Private Equity

Completed

Single Bidder

Acquisition

Friendly

Cross Border

home infusion

Private

Majority

Household Equipment and Products

United States

Synopsis

Edit

Novo, a healthcare investment firm, completed the acquisition of KabaFusion, a provider of essential acute, chronic, and enteral home infusion therapies, from Pritzker Private Capital, a private equity firm. Financial terms were not disclosed. "We have been extremely impressed with the pace of growth and service orientation of KabaFusion, which is a testament to their leading clinical knowledge in immunoglobulin therapies and patient-first approach. The investment in KabaFusion fits well with Novo Holdings' overall ambition of creating long-term value and making a positive impact on health, science, and society," Abhijeet Lele, Novo Senior Partner and Head of US Principal Investments.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US